Chemical Namebempedoic acid and ezetimibe
Dosage FormTablet (oral; bempedoic acid/ezetimibe: 180 mg/10 mg)
Drug ClassMultiple
Approval Year2020


  • Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Document TitleYearSource
Nexlizet (bempedoic acid and ezetimibe) Prescribing Information.2021Esperion Therapeutics, Inc., Ann Arbor, MI
Document TitleYearSource
VA/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. 2020Department of Veterans Affairs Department of Defense
Drug updated on 5/31/2023

More on this drug: Clinical Trials